Evicenter
Wegovy (semaglutide) in Chronic weight management
Manufacturer
Novo Nordisk Inc.
Prescribing information
Wegovy (opens in a new tab)
Questions
61
Last updated

All questions

Safety: Wegovy (semaglutide) in chronic weight management

11 questions · 3 sources

Side effects

What are the most common side effects of Wegovy?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

“Table 3 shows adverse reactions reported in greater than or equal to 2% of WEGOVY® 2.4 mg injection-treated adult patients and more frequently than in the placebo group from these trials. Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY® 2.4 mg Injection- treated Adults with Obesity or Overweight for Weight Reduction Placebo N=1,261 % WEGOVY® Injection (2.4 mg Once Weekly) N=2,116 % Nausea 16 44 Diarrhea 16 30 Vomiting 6 24 Constipation 11 24 Abdominal Paina 10 20 Headache 10 14 Fatigueb 5 11 Dyspepsia 3 9 Dizziness 4 8 Abdominal Distension 5 7 Eructation <1 7 Hypoglycemia in T2DMc 2 6 Flatulence 4 6 Gastroenteritis 4 6 Gastroesophageal Reflux Disease 3 5 Gastritisd 1 4 Gastroenteritis Viral 3 4 Hair Loss 1 3 Dysesthesiae 1 2 a Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort. b Includes fatigue and asthenia. c Defined as blood glucose <54 mg/dL with or without symptoms of hypoglycemia or severe hypoglycemia (requiring the assistance of another person) in patients with type 2 diabetes not on concomitant insulin (Study 3, WEGOVY® N=403, Placebo N=402). See text below for further information regarding hypoglycemia in patients with and without type 2 diabetes. T2DM = type 2 diabetes mellitus. d Includes chronic gastritis, gastritis, gastritis erosive, and reflux gastritis. e Includes paresthesia, hyperesthesia, burning sensation, allodynia, dysesthesia, skin burning sensation, pain of skin, and sensitive skin.” (opens the source at this quote in a new tab)

Note: Table 3 columns are placebo (N=1,261) then WEGOVY 2.4 mg injection (N=2,116), in % of patients, pooled from 3 placebo-controlled weight-reduction trials in adults.

How do Wegovy HD 7.2 mg side effects compare with 2.4 mg?

Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

“The safety of WEGOVY® 7.2 mg injection was evaluated in two 72-week double-blinded randomized placebo-controlled 3-armed trials (Study 8 and Study 9), including 1,311 patients with obesity (BMI ≥30 kg/m2) exposed in the treatment arm with WEGOVY® 7.2 mg injection, 304 patients exposed in the treatment arm with WEGOVY® 2.4 mg injection, and 303 patients exposed to placebo [see Clinical Studies (14.2)]. After dosage escalation, 1,149 patients received at least one dose of WEGOVY® 7.2 mg injection, and 578 patients received 7.2 mg for at least 1 year. Baseline characteristics in the WEGOVY® 7.2 mg injection arm included a mean age of 49 years, 70% female, 85% White, 5% Asian, 8% Black or African American, and 2% reported as other or unknown; and 5% were Hispanic or Latino ethnicity. At baseline, mean BMI was 39.5 kg/ m2, 52% with hypertension, 38% with dyslipidemia, 40% with a BMI greater than 40 kg/m2, and 14% with CV disease. In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY® injection, 5% of patients treated with 2.4 mg of WEGOVY® injection and 2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions. The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3%, 3%, and 0.3%, for WEGOVY® 7.2 mg injection, WEGOVY® 2.4 mg injection, and placebo, respectively. Table 4 shows adverse reactions reported in greater than or equal to 2% of WEGOVY® 7.2 mg injection and more frequently than 2.4 mg injection-treated and placebo-treated patients from these studies. Table 4. Adverse Reactions (2% and Greater Than WEGOVY® 2.4 mg and Placebo) in WEGOVY® 7.2 mg Injection-treated Adults with Obesity for Weight Reduction Placebo N=303 % WEGOVY® Injection (2.4 mg Once Weekly) N=304 % WEGOVY® Injection (7.2 mg Once Weekly) N=1,311 % Nausea 13 35 39 Vomiting 6 16 22 Dysesthesiaa 0 6 22 Constipation 8 19 20 Abdominal painb 7 9 12 Fatiguec 5 9 11 Headache 7 8 9 Dizzinessd 1 5 6 Hair loss 1 3 6 Flatulence 2 2 4 a Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization. b Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort. c Includes fatigue and asthenia. d Includes dizziness and dizziness postural.” (opens the source at this quote in a new tab)

Note: Table 4 columns are placebo (N=303), WEGOVY 2.4 mg (N=304), and WEGOVY 7.2 mg (N=1,311), in % of patients. The Clinical Product Review describes the same pool as the STEP UP and STEP UP T2D trials.

What are the side effects of the Wegovy pill?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

How long do Wegovy pill side effects such as nausea last?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

Note: These median durations are from OASIS 4 (Wegovy 25 mg tablets vs placebo) on the safety profile page of the Wegovy HCP site; the Prescribing Information does not report them.

How common is nausea on the Wegovy injection?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

How long does nausea last on Wegovy HD (STEP UP)?

Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

Note: These passages are from the STEP UP section of the safety profile page of the Wegovy HCP site; STEP UP compared Wegovy HD 7.2 mg, Wegovy 2.4 mg, and placebo. The page text does not state which STEP UP arm the 6-day median nausea duration describes; the accompanying chart is an image.

How can Wegovy nausea and stomach side effects be reduced?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

Note: The eating suggestions are from the dosing page of the Wegovy HCP site, which cites published references; they do not appear in the Prescribing Information.

How many people stop taking Wegovy because of side effects?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

Note: The last passage is from the trial of WEGOVY 25 mg tablets (Study 7).

Does Wegovy cause hair loss?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

Does Wegovy HD 7.2 mg cause skin pain, tingling, or burning (dysesthesia)?

Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

“Dysesthesia, and related events of altered skin sensations including paresthesia, pain of skin, sensitive skin, and burning skin sensation, occurred in clinical trials with WEGOVY® injection and tablet. The incidence of dysesthesia with WEGOVY® increased with increasing dosage and drug levels in the blood. In clinical trials evaluating patients with and without type 2 diabetes mellitus, WEGOVY® 7.2 mg injection dysesthesia was reported at a higher rate in the WEGOVY® 7.2 mg injection group (22%), compared to WEGOVY® 2.4 mg injection (6%) and placebo (0.3%). Among 288 patients who experienced dysesthesia with WEGOVY® 7.2 mg injection, 2% permanently discontinued treatment, 8% had temporary interruption, and 23% had dose reduction; most subjects with these actions taken to WEGOVY® 7.2 mg injection (permanent discontinuation, temporary interruption, or dose reduction) recovered from the event. When an action was taken with WEGOVY®, events resolved faster than the events where no action was taken with WEGOVY®. Among patients who experienced dysesthesia with WEGOVY® 7.2 mg injection, 18% did not report recovering during the trial duration; in most of the patients who did not recover, the WEGOVY® dosage was unchanged and not discontinued. Of the patients who recovered after action taken with WEGOVY®, 38 patients were re-escalated to 7.2 mg. Of these 38 patients, 17 (45%) subsequently reported recurrence of dysesthesia. In a clinical trial with WEGOVY® 25 mg tablets, 5% of WEGOVY®- treated patients and no placebo-treated patients reported dysesthesia adverse reactions.” (opens the source at this quote in a new tab)

Can Wegovy cause low blood pressure or fainting?

Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition